Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BAX | Q07812 | 2/20 | 0.88 |
| ▸ | MAPT | P10636 | 3/20 | 0.86 |
| ▸ | TP53 | P04637 | 1/20 | 0.86 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.86 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.86 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.86 |
| ▸ | MEN1 | O00255 | 3/20 | 0.78 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.78 |
| ▸ | RAD52 | P43351 | 2/20 | 0.78 |
| ▸ | IDO1 | P14902 | 1/20 | 0.62 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | ATM | Q13315 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | BACE1 | P56817 | 1/20 | 0.52 |
| ▸ | DNM1 | Q05193 | 3/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | GLA | P06280 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL607334 | 1.00 | BAX (0.88) | BAXMAPTTP53CYP3A4ALOX15 | |
| SCHEMBL607333 | 1.00 | BAX (0.88) | BAXMAPTTP53CYP3A4ALOX15 | |
| SCHEMBL29991749 | 0.94 | BAX (1.00) | BAXMAPTTP53CYP3A4ALOX15 | |
| SCHEMBL610221 | 0.94 | BAX (1.00) | BAXMAPTTP53CYP3A4ALOX15 | |
| SCHEMBL609455 | 0.94 | BAX (1.00) | BAXMAPTTP53CYP3A4ALOX15 | |
| SCHEMBL29716701 | 0.94 | BAX (1.00) | BAXMAPTTP53CYP3A4ALOX15 | |
| SCHEMBL609012 | 0.94 | BAX (1.00) | BAXMAPTTP53CYP3A4ALOX15 | |
| SCHEMBL29432619 | 0.94 | BAX (1.00) | BAXMAPTTP53CYP3A4ALOX15 | |
| Hydrochloric Acid SCHEMBL31457406 | 0.93 | MAPT (1.00) | BAXMAPTTP53CYP3A4ALOX15 | |
| Hydrochloric Acid SCHEMBL21085183 | 0.93 | MAPT (1.00) | BAXMAPTTP53CYP3A4ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1237887-B1 | 9-(PIPERAZINYLALKYL)CARBAZOLES AS BAX-MODULATORS | SERONO LAB (CH) | 2008-06-04 | — | — | EP | claimed |
| EP-1094063-A1 | 9-(Piperazinylalkyl)carbazoles as Bax-modulators | Applied Research Systems ARS Holding N.V. (AN) | 2001-04-25 | — | — | EP | claimed |
| US-8410110-B2 | 9-(piperazinylalkyl) carbazoles as Bax-modulators | MERCK SERONO SA (CH) | 2013-04-02 | — | — | US | disclosed |
| US-20120040933-A1 | 9-(PIPERAZINYLALKYL) CARBAZOLES AS BAX-MODULATORS | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2012-02-16 | — | — | US | disclosed |
| US-8053436-B1 | 9-(piperazinylalkyl) carbazoles as bax-modulators | MERCK SERONO SA (CH) | 2011-11-08 | — | — | US | disclosed |
| EP-1237887-B1 | 9-(PIPERAZINYLALKYL)CARBAZOLES AS BAX-MODULATORS | SERONO LAB (CH) | 2008-06-04 | — | — | EP | disclosed |
| EP-1094063-A1 | 9-(Piperazinylalkyl)carbazoles as Bax-modulators | Applied Research Systems ARS Holding N.V. (AN) | 2001-04-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040933-A1 | 9-(PIPERAZINYLALKYL) CARBAZOLES AS BAX-MODULATORS | BCL2, BAX, BAD | BAX 2/4885MAPT 1085/4885TP53 1113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.